CAS 96-50-4|2-Aminothiazole
Introduction：Basic information about CAS 96-50-4|2-Aminothiazole, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | 2-Aminothiazole | ||
|---|---|---|---|
| CAS Number | 96-50-4 | Molecular Weight | 100.142 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 216.4±9.0 °C at 760 mmHg |
| Molecular Formula | C3H4N2S | Melting Point | 91-93 °C(lit.) |
| MSDS | ChineseUSA | Flash Point | 84.7±18.7 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | 1,3-thiazol-2-amine |
|---|---|
| Synonym | More Synonyms |
2-Aminothiazole BiologicalActivity
| Description | Aminothiazole (2-Aminothiazole) is a beginning point for synthesis of many compounds including sulfur drugs, biocides, fungicides, dyes and chemical reaction accelerators.IC50 value:Target:2-Aminothiazole can be used as a thyroid inhibitor in the treatment of hyperthyroidism and it has antibacterial activity. Also used as the acid tartrate. Recent studies using prion-infected neuroblastoma cell lines have suggested that aminothiazole may be used as a therapeutic drug for prion diseases. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Others |
| References | [1]. Gallardo-Godoy A, et al. 2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem. 2011 Feb 24;54(4):1010-21. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 216.4±9.0 °C at 760 mmHg |
| Melting Point | 91-93 °C(lit.) |
| Molecular Formula | C3H4N2S |
| Molecular Weight | 100.142 |
| Flash Point | 84.7±18.7 °C |
| Exact Mass | 100.009521 |
| PSA | 67.15000 |
| LogP | 0.38 |
| Vapour Pressure | 0.1±0.4 mmHg at 25°C |
| Index of Refraction | 1.645 |
| InChIKey | RAIPHJJURHTUIC-UHFFFAOYSA-N |
| SMILES | Nc1nccs1 |
| Water Solubility | 100 g/L (20 ºC) |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 480 mg/kg
- TOXIC EFFECTS :
- Behavioral - tremor Behavioral - coma Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 570 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 200 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - cat
- DOSE/DURATION :
- 120 mg/kg
- TOXIC EFFECTS :
- Behavioral - tremor Behavioral - coma Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 370 mg/kg
- TOXIC EFFECTS :
- Behavioral - tremor Behavioral - coma Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 120 mg/kg
- TOXIC EFFECTS :
- Behavioral - tremor Behavioral - coma Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 4500 mg/kg/56D-I
- TOXIC EFFECTS :
- Liver - hepatitis (hepatocellular necrosis), zonal Liver - fatty liver degeneration Related to Chronic Data - death
- TYPE OF TEST :
- TCLo - Lowest published toxic concentration
- ROUTE OF EXPOSURE :
- Inhalation
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 200 mg/m3/7H/61D-I
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - fibrosis, focal (pneumoconiosis) Lungs, Thorax, or Respiration - dyspnea Related to Chronic Data - death
- TYPE OF TEST :
- TCLo - Lowest published toxic concentration
- ROUTE OF EXPOSURE :
- Inhalation
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 200 mg/m3/7H/30D-I
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - chronic pulmonary edema Related to Chronic Data - death
- TYPE OF TEST :
- TCLo - Lowest published toxic concentration
- ROUTE OF EXPOSURE :
- Inhalation
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 25 mg/m3/7H/62D-I
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - chronic pulmonary edema Liver - fatty liver degeneration Related to Chronic Data - death
MUTATION DATA - TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - mouse Lymphocyte
- DOSE/DURATION :
- 557 mg/L
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 155,17,1985
- TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - mouse Lymphocyte
- DOSE/DURATION :
- 557 mg/L
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 155,17,1985
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn:Harmful |
| Risk Phrases | R22;R36/37 |
| Safety Phrases | S26-S36/37-S39 |
| RIDADR | 2811 |
| WGK Germany | 3 |
| RTECS | XJ2100000 |
| Packaging Group | I; II; III |
| HS Code | 2934999090 |
Customs
| HS Code | 2934100090 |
|---|---|
| Summary | 2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
Articles34
More Articles| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ... | |
| Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorg. Med. Chem. 16 , 6193-206, (2008) Selective inhibitors of neuronal nitric oxide synthase (nNOS) were shown to protect brain and may be useful in the treatment of neurodegenerative diseases. In this context, our purpose has been to des... | |
| Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat. Neurourol. Urodyn. 34(4) , 368-74, (2015) We measured single-unit mechanosensitive afferent activities (SAAs) during reflexic, rhythmic bladder contractions (RBCs), and examined whether L-arginine, an NO substrate, and mirabegron, a β3-adreno... |
Synonyms
| thiazole-2-amine |
| EINECS 202-511-6 |
| usafek-p-5501 |
| 2-amino-1,3-thiazole |
| Aminothiazole |
| 1,3-Thiazol-2-amine |
| BASEDOL |
| 2-Aminothiazole |
| ABADOLE |
| 2-thiazolylamine |
| 2-amino-thiazole |
| aminothiazol |
| RP 2921 |
| 2-Thiazolamine |
| THIAZYLAMINE |
| Abadol |
| MFCD00005325 |
| thiazol-2-amine |
| cp1585 |
| 2-AMINO THIAZOLE |
